IONS (Ionis Pharmaceuticals) Current Deferred Taxes Liabilities: $0.0 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

IONS Ionis Pharmaceuticals Inc IONS
70 GF Score
Price $59.55
GF Value $48.10
Valuation Modestly Overvalued
! 4 Warning Signs
View Full Analysis

What is Ionis Pharmaceuticals Current Deferred Taxes Liabilities?

Ionis Pharmaceuticals IONS +1.57% 70 Current Deferred Taxes Liabilities is $0.0 Mil as of Jun. 2026. GuruFocus rates IONS with a GF Score™ of 70/100 and a GF Value™ of $48.10 (Modestly Overvalued). The stock has 4 warning signs investors should review.

Current Deferred Taxes Liabilities represent future tax liabilities, resulting from temporary differences between book (accounting) value of assets and liabilities and their tax value, or timing differences between the recognition of gains and losses in financial statements and their recognition in a tax computation. Deferred tax liabilities generally arise where tax relief is provided in advance of an accounting expense, or income is accrued but not taxed until received.

Ionis Pharmaceuticals's current deferred tax liabilities for the quarter that ended in Jun. 2026 was $0.0 Mil.

Ionis Pharmaceuticals Current Deferred Taxes Liabilities Related Terms

Ionis Pharmaceuticals Current Deferred Taxes Liabilities Historical Data

* Premium members only.

The historical data trend for Ionis Pharmaceuticals's Current Deferred Taxes Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Ionis Pharmaceuticals Current Deferred Taxes Liabilities Chart

Ionis Pharmaceuticals Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Current Deferred Taxes Liabilities
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Ionis Pharmaceuticals Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Current Deferred Taxes Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
IONS
70GF Score
Ionis Pharmaceuticals Inc IONS
Current Deferred Taxes Liabilities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
What does a Current Deferred Taxes Liabilities of $0.0 Mil mean?
Ionis Pharmaceuticals (IONS) has a Current Deferred Taxes Liabilities of $0.0 Mil as of Jun. 2026. Current Deferred Tax Liabilities records the total amount of taxes due for the period but not yet paid. View historical data on Ionis Pharmaceuticals and its competitors.
Is Ionis Pharmaceuticals' Current Deferred Taxes Liabilities too high?
Ionis Pharmaceuticals' current Current Deferred Taxes Liabilities is $0.0 Mil. Overall, Ionis Pharmaceuticals has a GF Score™ of 70/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Ionis Pharmaceuticals' Current Deferred Taxes Liabilities compare to KYMR and PRAX?
Ionis Pharmaceuticals' Current Deferred Taxes Liabilities of $0.0 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Current Deferred Taxes Liabilities for a Biotechnology company?
A good Current Deferred Taxes Liabilities depends on the Biotechnology industry context. However, Current Deferred Taxes Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Current Deferred Taxes Liabilities mean?
A high Current Deferred Taxes Liabilities can signal that a stock is expensive relative to its fundamentals. Current Deferred Tax Liabilities records the total amount of taxes due for the period but not yet paid. View historical data on Ionis Pharmaceuticals and its competitors. Ionis Pharmaceuticals's current Current Deferred Taxes Liabilities is $0.0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Ionis Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Ionis Pharmaceuticals (IONS) is currently considered Modestly Overvalued. The stock's GF Value™ is $48.10, compared to a current price of $59.55 — trading 23.8% above its estimated fair value. The current Current Deferred Taxes Liabilities is $0.0 Mil. Ionis Pharmaceuticals' overall GF Score™ is 70/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Current Deferred Taxes Liabilities calculated?
Current Deferred Taxes Liabilities is calculated from a company's financial statements. For Ionis Pharmaceuticals (IONS), the current Current Deferred Taxes Liabilities is $0.0 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Ionis Pharmaceuticals (IONS) Overvalued in 2026?

Based on GuruFocus' analysis, Ionis Pharmaceuticals stock appears to be overvalued. The current stock price of $59.55 is trading 23.8% above its estimated GF Value™ of $48.10. GuruFocus considers Ionis Pharmaceuticals to be Modestly Overvalued.

Key valuation signals for IONS:

  • Current Deferred Taxes Liabilities: $0.0 Mil
  • GF Value™: $48.10 vs. price of $59.55 (23.8% above fair value)
  • GF Score™: 70/100 with 4 warning signs

No single metric tells the full story. See the IONS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Ionis Pharmaceuticals Business Description

Address 2855 Gazelle Court, Carlsbad, CA, USA, 92010
Ionis Pharmaceuticals is the leading developer of antisense technology to discover and develop novel drugs. Its broad clinical and preclinical pipeline targets a wide variety of diseases, with an emphasis on cardiovascular, metabolic, neurological, and rare diseases. Ionis and Biogen brought Spinraza to market in 2016 as a treatment for spinal muscular atrophy, and Biogen launched ALS drug Qalsody in 2023. Ionis brought two additional drugs to market via its cardiovascular-focused subsidiary Akcea, including ATTR amyloidosis drug Tegsedi (2018) and cardiology drug Waylivra (Europe, 2019). Ionis and AstraZeneca launched polyneuropathy drug Wainua in 2024. Ionis marked its first two independent launches in 2025 for Tryngolza (for FCS) and Dawnzera (for HAE).
70GF Score

Get the complete analysis for IONS

Current Deferred Taxes Liabilities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$59.55
Price
$48.10
GF Value